Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials

References

• Felker GM, Adams KFJr, Konstam MA, et al. The problem of decompensated heart failure: Nomenclature, classification, and risk stratification. Am Heart J 2003;145:18-25
   PubMed Web of Science ®Google Scholar
• Carlson MD, Eckman PM. Review of vasodilators in acute decompensated heart failure: The old and the new. Am Heart J 2013;19:478-93
   Google Scholar
• Givertz MM, Teerlink JR, Albert NM, et al. Acute decompensated heart failure: Update on new and emerging evidence and directions for future research. Am Heart J 2013;19:371-89
   Google Scholar
• Heart Failure Society of A. Lindenfeld J, Albert NM, et al. Hfsa 2010 comprehensive heart failure practice guideline. Am Heart J 2010;16:e1-194
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Am Heart J 2013;62:e147-239
   Google Scholar
• Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47-72
   PubMed Web of Science ®Google Scholar
• Okumura K, Yasue H, Fujii H, et al. Effects of brain (b-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: Comparison with effects on systemic hemodynamic variables. J Am Coll Cardiol 1995;25:342-8
   PubMed Web of Science ®Google Scholar
• Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-6
   PubMed Web of Science ®Google Scholar
• Gassanov N, Biesenbach E, Caglayan E, et al. Natriuretic peptides in therapy for decompensated heart failure. Eur J Clin Pharmacol 2012;68:223-30
   Google Scholar
• Liang F, O’Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating b-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8
   PubMed Web of Science ®Google Scholar
• Schellenberger U, O’Rear J, Guzzetta A, et al. The precursor to b-type natriuretic peptide is an o-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6
   PubMed Web of Science ®Google Scholar
• Seferian KR, Tamm NN, Semenov AG, et al. Immunodetection of glycosylated nt-proBNP circulating in human blood. Clin Chem 2008;54:866-73
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Korinek J, Chen HH, et al. Nesiritide in acute decompensated heart failure: Current status and future perspectives. Rev Cardiovasc Med 2008;9:151-8
   Google Scholar
• Apple FS, Wu AH, Jaffe AS, et al. National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation 2007;116:e95-8
   Google Scholar
• Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am Heart J 2004;94:595-601
   Google Scholar
• Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004;94:595-601
   PubMed Web of Science ®Google Scholar
• Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: Results of the second follow-up serial infusions of nesiritide (FUSION II) trial. Circ Heart Fail 2008;1:9-16
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VI. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531-40
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5
   PubMed Web of Science ®Google Scholar
• Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2007;50:1835-40
   PubMed Web of Science ®Google Scholar
• Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the adhere database. J Card Fail 2007;13:422-30
   PubMed Web of Science ®Google Scholar
• Chow SL, O’Barr SA, Peng J, et al. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. J Card Fail 2011;17:181-7
   Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43
   PubMed Web of Science ®Google Scholar
• Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The rose acute heart failure randomized trial. JAMA 2013;310:2533-43
   PubMed Web of Science ®Google Scholar
• WT A. Serum creatinine elevations in patients receiving nesiritide are related to starting dose [abstract]. Circulation 2005;112:589
   Google Scholar
• Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine [abstract]. Circulation 2005;112:451-2
   Google Scholar
• Chow SL, Peng JT, Okamoto MP, Heywood JT. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients. Ann Pharmacother 2007;41:556-61
   Google Scholar
• Chow SL, O’Barr SA, Peng J, et al. Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: An exploratory study. Circ Heart Fail 2011;4:450-5
   Google Scholar
• Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev 2009;14:309-19
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Luss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: A double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005;150:1239
   PubMed Web of Science ®Google Scholar
• Luss H, Mitrovic V, Seferovic PM, et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008;155:1012 e1011-18
   Google Scholar
• Dickey DM, Burnett JCJr, Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008;283:35003-9
   Google Scholar
• Lee CY, Chen HH, Lisy O, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009;49:668-73
   PubMed Web of Science ®Google Scholar